PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma...
TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent glioblastoma (rGBM) in two manuscripts published in...
LEXINGTON, Mass., Jan. 8, 2020 /PRNewswire/ — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first patient with AGEN1223. AGEN1223 is a novel...
Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA Milan, Italy and Morristown, NJ, USA, January 9, 2020 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:...
Vault Payments enables sponsors and CROs to automatically create, track, and report payments in Vault CTMS for greater accuracy and visibility BARCELONA, Spain–(BUSINESS WIRE)–Veeva Systems (NYSE:VEEV) today introduced Veeva Vault Payments, a new add-on...
Email
Text